14 results about "Placental disc" patented technology

It is an object of the present invention to effectively promote growth of granulation tissue at a dermal defect or a subcutaneous tissue defect caused by a severe burn. To achieve this object, burn treatment cells for use in treatment of burns are composed of placenta-derived cells of an animal and promote healing.

Disclosed herein are methods of reducing pathological inflammation and effects thereof through administration of tissues associated with regenerative and / or tolerogenic activity. In some embodiments, such tissues can include placental, ocular, testicular, and osseous tissues. Augmentation of therapeutic effects of said tissues may be achieved through contact with Injury Mimetics.

The inventions relates to Immunoglobulin A (IgA) or a pharmaceutical composition comprising IgA for use in the treatment of an infectious disease of or in an immune privileged organ, such as the eye, fetus, placenta, central nervous system (CNS) and / or testicles caused by a bacterial, fungal, viral or parasitic infection, in particular caused by bacteria of the human microbiome. IgA-coated pathogens can be addressed by FCAR+ and / or CD11c+ innate immune cells, for example by phagocytosis, or by activation of the complement system. The use of IgA or a pharmaceutical composition comprising IgA in immune privileged sites is advantageous because in contrast to IgG, IgA-coated pathogens do not trigger activation of C1q, a protein used for the controlled pruning of synapses. This prevents neuronal damage in said immune privileged organ(s), while at the same time allowing an antibody-mediated immune response in said organs.

FIELD: oncology.SUBSTANCE: used to treat malignant embryonic tumors. The method involves pharmacological inhibition of factors that support tumor growth. A progesterone receptor antagonist is administered and immunological activation of the body's response against progesterone-induced blocking factor (PIBF), placental growth factor (PIGF) and trophoblastic β 1-glycoprotein.EFFECT: increased treatment reliability due to a comprehensive and selective effect on the tumor, simultaneous influence on both the primary tumor site and metastases, a reduction in the likelihood of relapse due to the destruction of the tumor vascular network, and a reduction in the overall toxic load on the patient's body during treatment.7 cl, 1 tbl, 5 ex

The present invention relates to a biomarker for diagnosing neuromyelitis optica and its use. Specifically, the present invention relates to a biomarker composition for diagnosing neuromyelitis optica comprising one or more genes selected from the group consisting of Plac8 (placenta-specific 8), Klra2 (killer cell lectin-like receptor, subfamily A, member 2) and Mcoln2 (mucolipin 2) or a protein expressed from said genes; a composition for diagnosing neuromyelitis optica comprising a substance for measuring the mRNA level of said genes or the protein level thereof; a diagnostic kit for neuromyelitis optica comprising said composition; and a method for providing information for predicting and diagnosing neuromyelitis optica.

This invention provides a method for performing a placental assessment. The method includes obtaining a 3D ultrasound image of the uterus (210) and segmenting the placenta (220). A 3D map (200) of the uterus is then generated, wherein the generation includes: identifying the location of the placenta within the uterus relative to anatomical structures such as the cervix (250); obtaining anatomical reference data regarding potential risks associated with the location of the placenta within the uterus; and comparing the location of the placenta with the anatomical reference data. Generating the 3D map of the uterus includes a 3D map of the placenta marked with indicators that change based on the comparison of the placenta's location with the anatomical reference data. The appearance of the indicators can be changed according to, for example, risk type / severity.

The invention is directed to a composition of soluble placental ECM in storage solution and the methods of manufacture related thereto. The solubilized placental ECM solution is manufactured through a process of partitioning placental ECM from the placental tissue in a high acidic pH environment and performing an ultrafiltration step and diafiltration step through a tangential flow filtration system to increase the pH. The soluble placental ECM retains the native characteristics of placental ECM components and includes collagens (types I, III, V, VI, IX, and X), elastin, laminin, and fibronectin.

This invention discloses a placental tissue sampling robot, comprising a support frame, a support platform, an identification device, and a moving device. The support platform is mounted on the support frame. The identification device is mounted on the support frame, facing the support platform, and is used to identify and locate the required cutting position of the placenta. The moving device is mounted on the support frame, and its moving end is equipped with a clamping component, which is located above the support platform. Both clamping ends of the clamping component are equipped with cutting components. The moving device controls the cutting components to cut the placenta at the designated cutting position based on the identification and positioning of the required cutting position by the identification device. A frame-shaped cutting section is provided on the side of each cutting component facing the other. When the clamping component is closed, the two frame-shaped cutting sections are tangent to remove a placental sample of the corresponding frame size. Through these features, the robot can automatically avoid unsampling areas and achieve automated cutting and sampling of precise sampling points in safe, non-calcified areas.

The present application relates to the field of medical information technology, and particularly relates to a placenta position detection system and method based on MRI, the method comprising: obtaining target MRI image data, performing image segmentation processing on the target MRI image data, and extracting three-dimensional models of the placenta, uterus and cervix; based on the three-dimensional models, identifying the positional relationship between the placenta and the cervix, judging the placenta type, and evaluating the placenta implantation risk to generate risk warning information; displaying a three-dimensional visual model of the placenta and the uterus, and labeling a high-risk area on the three-dimensional visual model based on the risk warning information. The present application improves the placenta position detection efficiency, precision and automation, can realize full-process automatic detection, and reduces human error.

This application provides a polypeptide whose amino acid sequence includes the amino acid sequence shown in SEQ ID NO.1. The amino acid sequence of SEQ ID NO.1 is GPPVSE. This application also provides the application of the above-mentioned polypeptide in medical aesthetics and tissue repair products that promote cell proliferation and migration and endothelial tube formation. This application also provides a tissue repair product comprising the above-mentioned polypeptide. This application conducts research and development on polypeptide components in placental polypeptide extracts, and identifies and screens a monomeric polypeptide component that promotes tissue repair from placental polypeptide extracts.

Provided herein is a placental product comprising an immunocompatible chorionic membrane. Such placental products can be cryopreserved and contain viable therapeutic cells after thawing. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment.

A method of preparing sterile human placental allografts by providing a human placental tissue from a donor within 24 hours to 72 hours post-childbirth; removing any visible blood, blood clots, and / or blood components from the human placental tissue without scraping or scrubbing the human placental tissue to preserve structural integrity of the human placental tissue; washing the human placental tissue in an isotonic solution while maintaining the structural integrity of the human placental tissue; dehydrating the human placental tissue thereby forming the dehydrated human placental tissue; resizing the dehydrated human placental tissue into dehydrated human placental tissue portions having predetermined sizes; and sterilizing the dehydrated human placental tissue portions of step (e) thereby forming the sterile human placental allograft. Also disclosed is a sterile human placental allograft produced by the method.

Provided herein are new and useful placental derived natural killer (NK) Cell or population thereof, or one or more cells within the population that express a cleavage resistant CD 16 polypeptide and a secreted IL-15 polypeptide, as well as uses thereof.